 |
| |
 | | Hospitalization | |
|
Hospitalize all patients for inhalational anthrax, gastrointestinal anthrax, anthrax meningitis, and severe cutaneous anthrax.  |
- Hospitalize patients with:
- Confirmed inhalational anthrax, gastrointestinal anthrax, or anthrax meningitis
- Severe cutaneous disease, including those with systemic illness (fevers, chills) and those with lesions on the face and neck
- High-risk exposure during an anthrax bioterrorist attack who present with flu-like illness with fever, headache, and muscle ache, or signs of disease on laboratory or radiologic tests (i.e., widened mediastinum)
- Use standard precautions for patients infected with anthrax without respiratory isolation.
- Discharge patients when they are stable and can take oral antibiotics.
| Background
| | | FAQs |
|
| Barbara Robinson-Dunn, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Demetrios N. Kyriacou, MD, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Niklas Mackler, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sandro Cinti, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Anthrax
